Omnipaque 140 Side Effects

Generic Name: iohexol

Note: This page contains side effects data for the generic drug iohexol. It is possible that some of the dosage forms included below may not apply to the brand name Omnipaque 140.

It is possible that some side effects of Omnipaque 140 may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Applies to iohexol: injectable solution

Gastrointestinal

Gastrointestinal side effects have been reported. In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using iohexol (the active ingredient contained in Omnipaque 140) 350, the following adverse reactions were reported: diarrhea (42%), nausea (15%), vomiting (11%), abdominal pain (7%), and flatulence (2%).
In controlled clinical studies involving 44 adult patients for dilute oral plus intravenous CT examination of the gastrointestinal tract using iohexol 300, adverse reactions were limited to a single report of vomiting (2%).

Oral administration of iohexol is most often associated with mild, transient diarrhea especially when high concentrations and large volumes are administered. Nausea, vomiting, and moderate diarrhea have also been reported following orally administered iohexol, but much less frequently.

Flatulence, diarrhea, nausea, vomiting, abdominal pressure (all less than or equal to 1%) have been reported following oral/ body administration for various body cavity examinations.

Gastrointestinal system side effects following herniography have included flatulence (10%) and diarrhea (3%).

Gastrointestinal side effects reported from endoscopic retrograde pancreatography (ERP)/endoscopic retrograde cholangiopancreatography (ERCP) have been vomiting, diarrhea, and pressure (1% each).

Nervous system

Nervous system side effects following arthrography have included swelling sensation (42%), pain (29%), heat sensation (13%), and muscle weakness (0.7%).

Pain (26%) and headache, somnolence, fever, muscle weakness, burning, unwell feeling, tremors, lightheadedness, syncope (all less than or equal to 1%) have been reported following oral/ body administration for various body cavity examinations.

Nervous system side effects reported from endoscopic retrograde pancreatography (ERP)/endoscopic retrograde cholangiopancreatography (ERCP) have been pain (17%), somnolence (1%), and burning (1%).

Nervous system side effects in cerebral arteriography have included photomas (15%), headache (5.5%), and pain (4.5%). Cerebral arteriography with water-soluble contrast media has been associated with temporary neurologic complications including seizures, drowsiness, and transient paresis.

Nervous system side effects following herniography have included pain (7%), headache (3%), and unwell feeling (3%).

Nervous system side effects from intra-arterial digital angiography have included transient ischemia attacks (1.6%) and cerebral infarctions (1.6%). These occurred in high risk patients having a cerebral examination and the relationship to the contrast medium was uncertain. Headache occurred in 6.3% of the patients, all of whom were having cerebral examinations.

In controlled clinical trials involving 54 adult patients for oral pass-thru examination of the gastrointestinal tract using iohexol (the active ingredient contained in Omnipaque 140) 350, headache (2%) has been reported.

Dermatologic

Dermatologic side effects including swelling (22%) and heat (7%) have been reported following oral/ body administration for various body cavity examinations.

General

General side effects have included leg pain (21%) during phlebography.

Injection of iohexol (the active ingredient contained in Omnipaque 140) in endoscopic retrograde pancreatography (ERP)/endoscopic retrograde cholangiopancreatography (ERCP) has been associated with transient pain. However, delayed, severe or persistent pain may occur and can persist for 24 hours.

Cardiovascular

Cardiovascular side effects in angiocardiography included angina (8%), hypotension (2.5%), bradycardia (1.0%), and tachycardia (1.0%).

Cardiovascular side effects reported in digital arteriography have included transient PVCs (16%) and PACs (6.5%). Hypertension (less than or equal to 1%) has been reported following oral/ body administration for various body cavity examinations.

Cardiovascular side effects reported from endoscopic retrograde pancreatography (ERP)/endoscopic retrograde cholangiopancreatography (ERCP) have been hypertension (1%).

Local

Local side effects including hematoma at injection site (less than or equal to 1%) have been reported following oral/ body administration for various body cavity examinations.

Ocular

Ocular side effects have been reported. Cerebral arteriography with water-soluble contrast media has been associated with and mild disturbances in vision such as photomas of one-second or less duration.

Musculoskeletal

Severe pain may often result from undue use of pressure or the injection of large volumes. Joint swelling after injection is less with iohexol (the active ingredient contained in Omnipaque 140) than with high osmolar ionic contrast medium. These types of reactions are generally procedurally dependent and of greater frequency when double-contrast technique is employed.

Musculoskeletal side effects from injection of iohexol into the joint have been transient discomfort including pain and swelling. However, delayed, severe or persistent discomfort may occur occasionally.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web4)